Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All convalescent plasma..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchConvalescent PlasmaConv. Plasma (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients

Bajpai et al., Anais da Academia Brasileira de Ciências, doi:10.1590/0001-3765202220210202, ILBS-COVID-02, NCT04346446
Oct 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -323% Improvement Relative Risk Mortality (b) -114% Ventilation -221% Hospitalization time 25% Improvement in Ct value 33% Conv. Plasma  ILBS-COVID-02  LATE TREATMENT  RCT Is late treatment with convalescent plasma beneficial for COVID-19? RCT 29 patients in India Higher mortality (p=0.22) and ventilation (p=0.33), not sig. c19early.org Bajpai et al., Anais da Academia Brasi.., Oct 2020 Favorsconv. plasma Favorscontrol 0 0.5 1 1.5 2+
RCT 29 severe COVID-19 patients showing no significant differences with convalescent plasma compared to fresh frozen plasma.
risk of death, 323.0% higher, HR 4.23, p = 0.22, treatment 3 of 14 (21.4%), control 1 of 15 (6.7%), adjusted per study, 28 days, Cox proportional hazards.
risk of death, 114.3% higher, RR 2.14, p = 0.60, treatment 2 of 14 (14.3%), control 1 of 15 (6.7%), 7 days.
risk of mechanical ventilation, 221.4% higher, RR 3.21, p = 0.33, treatment 3 of 14 (21.4%), control 1 of 15 (6.7%), 7 days.
hospitalization time, 24.9% lower, relative time 0.75, p = 0.08, treatment 14, control 15.
relative improvement in Ct value, 33.1% better, RR 0.67, p = 0.11, treatment 14, control 15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bajpai et al., 27 Oct 2020, Randomized Controlled Trial, India, peer-reviewed, mean age 48.2, 17 authors, trial NCT04346446 (history) (ILBS-COVID-02).
This PaperConv. PlasmaAll
Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients
Meenu Bajpai, Ashish Maheshwari, Suresh Kumar, Karan Chhabra, Pratibha Kale, Ashad Narayanan, Amita Gupta, Ekta Gupta, Nirupama Trehanpati, Reshu Agarwal, Kamini Gupta, MOJAHIDUL ISLAM Ankit Bhardwaj, Mojahidul Islam, Ravinder Singh, Pushpa Yadav, Guresh Kumar, Shiv K Sarin
Anais da Academia Brasileira de Ciências, doi:10.1590/0001-3765202220210202
background: Role of Convalescent plasma (COPLA) to treat severe COVID-19 is under investigation. We compared effi cacy and safety of COPLA with fresh frozen plasma (FFP) in severe COVID-19 patients. Methods: One group received COPLA with standard medical care (n = 14), and another group received random donor FFP, as control with standard medical care (n = 15) in severe COVID-19 disease. Results: The proportion of patients free of ventilation at day seven were 78.5% in COPLA group, and 93.3 % in control group were not signifi cant (p= 0.258). However, improved respiratory rate, O2 saturation, SOFA score, and Ct value were observed in the COPLA group. No serious adverse events were noticed by plasma transfusion in both groups.
Author contributions 1.Study concept and design: Shiv K Sarin, Meenu Bajpai, Ashish Maheshwari, Suresh Kumar and Ekta Gupta. 2.Acquisition of data: Karan Chhabra, Ashad Narayan, Pratibha Kale, Amita Gupta, Reshu Agarwal, Kamini Gupta, Mojahidul Islam, Ravinder Singh and Pushpa Yadav. 3. Statistical analysis: Guresh Kumar, Ankit Bhardwaj. 4.Initial Drafting of the Manuscript: Suresh Kumar, Ashish Maheshwari, Pratibha Kale, Ekta Gupta, Nirupama Trehanpati, Karan Chhabra, Ankit Bhardwaj, Ashad Narayan, Amita Gupta, Reshu Agarwal, Kamini Gupta, Mojahidul Islam, Ravinder Singh and Pushpa Yadav. 5.Critical revision of manuscript done for important intellectual content: Meenu Bajpai, Guresh Kumar and Shiv K Sarin, 6.Administrative and technical support: Shiv K Sarin.
References
Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentrerandomised controlled trial (PLACID trial), BMJ
Al, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med
Al, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Chen, Xiong, Shi Y, Convalescent plasma as a potential therapy for COVID-19, Lancet Infect Dis
De, Brito, Lc, Cf, Correia et al., The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneumonia, BMC Pulm Med
Duan, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, ProcNatlAcadSci USA
Grein, Compassionate Use of Remdesivir for Patients with Severe Covid-19, N Engl J Med
Huang, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Joyner, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients, Mayo ClinProc
Li, Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomised Clinical Trial, JAMA
Libster, Early high-titer plasma therapy to prevent severe Covid-19 in older adults, N Engl J Med
Ng, Viral Load and Sequence Analysis Reveal the Symptom Severity, Diversity, and Transmission Clusters of Rhinovirus Infections, Clin Infect Dis
Recovery, Group, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Rules, Section XB and XIIB
Shen, Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma, JAMA
Straat, Mca, Jcm, Ms, Ames et al., effect of transfusion of fresh frozen plasma on parameters of
{ 'indexed': {'date-parts': [[2024, 7, 23]], 'date-time': '2024-07-23T15:04:53Z', 'timestamp': 1721747093768}, 'reference-count': 19, 'publisher': 'FapUNIFESP (SciELO)', 'license': [ { 'start': { 'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T00:00:00Z', 'timestamp': 1640995200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}, { 'start': { 'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T00:00:00Z', 'timestamp': 1640995200000}, 'content-version': 'am', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}, { 'start': { 'date-parts': [[2022, 1, 1]], 'date-time': '2022-01-01T00:00:00Z', 'timestamp': 1640995200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022]]}, 'DOI': '10.1590/0001-3765202220210202', 'type': 'journal-article', 'created': {'date-parts': [[2022, 9, 9]], 'date-time': '2022-09-09T20:21:28Z', 'timestamp': 1662754888000}, 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe ' 'covid-19 patients', 'prefix': '10.1590', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-4872-7845', 'authenticated-orcid': False, 'given': 'MEENU', 'family': 'BAJPAI', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0716-939X', 'authenticated-orcid': False, 'given': 'ASHISH', 'family': 'MAHESHWARI', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8766-6937', 'authenticated-orcid': False, 'given': 'SURESH', 'family': 'KUMAR', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5710-7026', 'authenticated-orcid': False, 'given': 'KARAN', 'family': 'CHHABRA', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5172-0193', 'authenticated-orcid': False, 'given': 'PRATIBHA', 'family': 'KALE', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2531-1094', 'authenticated-orcid': False, 'given': 'ASHAD', 'family': 'NARAYANAN', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-1369-9853', 'authenticated-orcid': False, 'given': 'AMITA', 'family': 'GUPTA', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5237-216X', 'authenticated-orcid': False, 'given': 'EKTA', 'family': 'GUPTA', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-6109-0033', 'authenticated-orcid': False, 'given': 'NIRUPAMA', 'family': 'TREHANPATI', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9207-3607', 'authenticated-orcid': False, 'given': 'RESHU', 'family': 'AGARWAL', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2091-1007', 'authenticated-orcid': False, 'given': 'KAMINI', 'family': 'GUPTA', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5380-2782', 'authenticated-orcid': False, 'given': 'ANKIT', 'family': 'BHARDWAJ', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7219-9686', 'authenticated-orcid': False, 'given': 'MOJAHIDUL', 'family': 'ISLAM', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0603-8328', 'authenticated-orcid': False, 'given': 'RAVINDER', 'family': 'SINGH', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5285-7936', 'authenticated-orcid': False, 'given': 'PUSHPA', 'family': 'YADAV', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8864-3849', 'authenticated-orcid': False, 'given': 'GURESH', 'family': 'KUMAR', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0544-5610', 'authenticated-orcid': False, 'given': 'SHIV K.', 'family': 'SARIN', 'sequence': 'additional', 'affiliation': []}], 'member': '530', 'reference': [ { 'key': 'ref1', 'article-title': 'PLACID Trial Collaborators', 'volume': '371', 'author': 'AGARWAL A', 'year': '2020', 'journal-title': 'BMJ'}, { 'issue': '19', 'key': 'ref2', 'doi-asserted-by': 'crossref', 'first-page': '1787', 'DOI': '10.1056/NEJMoa2001282', 'article-title': 'A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe ' 'Covid-19', 'volume': '382', 'author': 'CAO B', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '4', 'key': 'ref3', 'doi-asserted-by': 'crossref', 'first-page': '398', 'DOI': '10.1016/S1473-3099(20)30141-9', 'article-title': 'Convalescent plasma as a potential therapy for COVID-19', 'volume': '20', 'author': 'CHEN L', 'year': '2020', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '10223', 'key': 'ref4', 'doi-asserted-by': 'crossref', 'first-page': '507', 'DOI': '10.1016/S0140-6736(20)30211-7', 'article-title': 'Epidemiological and clinical characteristics of 99 cases of 2019 novel ' 'coronavirus pneumonia in Wuhan, China: a descriptive study', 'volume': '395', 'author': 'CHEN N', 'year': '2020', 'journal-title': 'Lancet'}, { 'issue': '1', 'key': 'ref5', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s12890-016-0324-z', 'article-title': 'The balance between the serum levels of IL-6 and IL-10 cytokines ' 'discriminates mild and severe acute pneumonia', 'volume': '16', 'author': 'DE BRITO RC', 'year': '2016', 'journal-title': 'BMC Pulm Med'}, { 'key': 'ref6', 'series-title': 'Section XB and XIIB, Ministry of Health and Family Welfare Govt. of ' 'India', 'author': 'DRUGS AND COSMETICS ACT AND RULES', 'year': '1940'}, { 'issue': '17', 'key': 'ref7', 'doi-asserted-by': 'crossref', 'first-page': '9490', 'DOI': '10.1073/pnas.2004168117', 'article-title': 'Effectiveness of convalescent plasma therapy in severe COVID-19 ' 'patients', 'volume': '117', 'year': '2020', 'journal-title': 'ProcNatlAcadSci USA'}, { 'issue': '24', 'key': 'ref8', 'doi-asserted-by': 'crossref', 'first-page': '2327', 'DOI': '10.1056/NEJMoa2007016', 'article-title': 'Compassionate Use of Remdesivir for Patients with Severe Covid-19', 'volume': '382', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '10223', 'key': 'ref9', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'volume': '395', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': 'ref10', 'doi-asserted-by': 'crossref', 'first-page': '1888', 'DOI': '10.1016/j.mayocp.2020.06.028', 'article-title': 'Safety update: COVID-19 convalescent plasma in 20,000 hospitalized ' 'patients', 'volume': '95', 'year': '2020', 'journal-title': 'Mayo ClinProc'}, { 'key': 'ref11', 'doi-asserted-by': 'crossref', 'first-page': '610', 'DOI': '10.1056/NEJMoa2033700', 'article-title': 'Early high-titer plasma therapy to prevent severe Covid-19 in older ' 'adults', 'volume': '384', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': 'ref12', 'doi-asserted-by': 'crossref', 'first-page': '460', 'DOI': '10.1001/jama.2020.10044', 'article-title': 'Effect of Convalescent Plasma Therapy on Time to Clinical Improvement ' 'in Patients With Severe and Life-threatening COVID-19: A Randomised ' 'Clinical Trial', 'volume': '324', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '2', 'key': 'ref13', 'doi-asserted-by': 'crossref', 'first-page': '261', 'DOI': '10.1093/cid/ciy063', 'article-title': 'Viral Load and Sequence Analysis Reveal the Symptom Severity, ' 'Diversity, and Transmission Clusters of Rhinovirus Infections', 'volume': '67', 'year': '2018', 'journal-title': 'Clin Infect Dis'}, { 'issue': '8', 'key': 'ref14', 'doi-asserted-by': 'crossref', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'article-title': '“Dexamethasone in Hospitalized Patients with Covid-19', 'volume': '384', 'author': 'RECOVERY COLLABORATIVE GROUP', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'issue': '16', 'key': 'ref15', 'doi-asserted-by': 'crossref', 'first-page': '1582', 'DOI': '10.1001/jama.2020.4783', 'article-title': 'Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent ' 'Plasma', 'volume': '323', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '1', 'key': 'ref16', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s13054-015-0828-6', 'article-title': 'effect of transfusion of fresh frozen plasma on parameters of ' 'endothelial condition and inflammatory status in non-bleeding ' 'critically ill patients: a prospective substudy of a randomized trial', 'volume': '19', 'author': 'STRAAT M', 'year': '2015', 'journal-title': 'Crit Care'}, { 'issue': '7', 'key': 'ref17', 'doi-asserted-by': 'crossref', 'first-page': '619', 'DOI': '10.1056/NEJMoa2031304', 'article-title': 'A randomized trial of convalescent plasma in covid-19 severe pneumonia', 'volume': '384', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'issue': '13', 'key': 'ref18', 'doi-asserted-by': 'crossref', 'first-page': '1239', 'DOI': '10.1001/jama.2020.2648', 'article-title': 'Characteristics of and Important Lessons From the Coronavirus Disease ' '2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases ' 'From the Chinese Center for Disease Control and Prevention', 'volume': '323', 'author': 'WU Z', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '1', 'key': 'ref19', 'article-title': 'Treatment With Convalescent Plasma for Critically Ill Patients With ' 'Severe Acute Respiratory Syndrome Coronavirus 2 Infection', 'volume': '158', 'year': '2020', 'journal-title': 'Chest'}], 'container-title': 'Anais da Academia Brasileira de Ciências', 'original-title': [], 'link': [ { 'URL': 'http://www.scielo.br/scielo.php?script=sci_pdf&pid=S0001-37652022000600701&tlng=en', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 10, 17]], 'date-time': '2022-10-17T13:13:37Z', 'timestamp': 1666012417000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.scielo.br/j/aabc/a/sFk4vCTR69vjG9wTsKHxLwC/?lang=en#'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022]]}, 'references-count': 19, 'URL': 'http://dx.doi.org/10.1590/0001-3765202220210202', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.1101/2020.10.25.20219337', 'asserted-by': 'object'}]}, 'ISSN': ['0001-3765'], 'subject': [], 'container-title-short': 'An. Acad. Bras. Ciênc.', 'published': {'date-parts': [[2022]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit